ranolazine
Generic: ranolazine
Labeler: sciegen pharmaceuticals, incDrug Facts
Product Profile
Brand Name
ranolazine
Generic Name
ranolazine
Labeler
sciegen pharmaceuticals, inc
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Routes
Active Ingredients
ranolazine 1000 mg/1
Manufacturer
Identifiers & Regulatory
Product NDC
50228-424
Product ID
50228-424_2a0ac71c-e53c-5ff9-e063-6394a90a4807
Product Type
HUMAN PRESCRIPTION DRUG
Marketing Category
ANDA
Application Number
ANDA211829
Listing Expiration
2026-12-31
Marketing Start
2019-06-04
Pharmacologic Class
Established (EPC)
Mechanism of Action
Normalized Code Variants
Searchable formats for this product NDC code
Digits Only
50228424
Hyphenated Format
50228-424
Supplemental Identifiers
RxCUI
UPC
UNII
NUI
Packaging Origin
Original Packager
Resolved Product View
Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.
Resolved Identity
Brand Name
ranolazine (source: ndc)
Generic Name
ranolazine (source: ndc)
Application Number
ANDA211829 (source: ndc)
Routes
source: ndc
Resolved Composition
Strengths
- 1000 mg/1
Packaging
- 500 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (50228-424-05)
- 30 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (50228-424-30)
- 60 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (50228-424-60)
Packages (3)
Ingredients (1)
Linked Drug Pages (1)
Raw FDA Data
View complete raw FDA NDC JSON payload
{"route": ["ORAL"], "spl_id": "2a0ac71c-e53c-5ff9-e063-6394a90a4807", "openfda": {"nui": ["N0000175427", "N0000190114", "N0000185503", "N0000182137", "N0000187061"], "upc": ["0350228424608", "0350228424301", "0350228423304", "0350228423601"], "unii": ["A6IEZ5M406"], "rxcui": ["616749", "728231"], "spl_set_id": ["71d50258-75b7-4801-b0f4-c34fe883d57d"], "pharm_class_epc": ["Anti-anginal [EPC]"], "pharm_class_moa": ["Cytochrome P450 3A Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]"], "manufacturer_name": ["ScieGen Pharmaceuticals, Inc"], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "500 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (50228-424-05)", "package_ndc": "50228-424-05", "marketing_start_date": "20190604"}, {"sample": false, "description": "30 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (50228-424-30)", "package_ndc": "50228-424-30", "marketing_start_date": "20190604"}, {"sample": false, "description": "60 TABLET, FILM COATED, EXTENDED RELEASE in 1 PACKAGE (50228-424-60)", "package_ndc": "50228-424-60", "marketing_start_date": "20190604"}], "brand_name": "RANOLAZINE", "product_id": "50228-424_2a0ac71c-e53c-5ff9-e063-6394a90a4807", "dosage_form": "TABLET, FILM COATED, EXTENDED RELEASE", "pharm_class": ["Anti-anginal [EPC]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 3A Inhibitors [MoA]", "Organic Cation Transporter 2 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "product_ndc": "50228-424", "generic_name": "RANOLAZINE", "labeler_name": "ScieGen Pharmaceuticals, Inc", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "RANOLAZINE", "active_ingredients": [{"name": "RANOLAZINE", "strength": "1000 mg/1"}], "application_number": "ANDA211829", "marketing_category": "ANDA", "marketing_start_date": "20190604", "listing_expiration_date": "20261231"}